RxDoctor Payments Data

Tricia McGillis, PA

Physician Assistant · Marion, MINPI 1619989530

Payments from drug & device makers

$3,650in general payments, 2019–2025

Across 208 payments — averaging $17.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$593
  • AbbVie$478
  • GSK$399
  • Otsuka America Pharmaceutical, Inc.$352
  • Electromed, Inc.$258
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$249
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,60399%
  • Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,650 in reported general payments places this provider in the 90th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$93,156
Medicare patients
81
Services billed
1,735

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide46$89,754
TrulicityDulaglutide51$65,461
FarxigaDapagliflozin Propanediol69$55,759
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$55,286
Xigduo XrDapaglifloz Propaned/Metformin45$43,632
EliquisApixaban55$37,771
CreonLipase/Protease/Amylase20$25,748
JardianceEmpagliflozin37$25,302
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog21$23,844
XareltoRivaroxaban20$19,509
VraylarCariprazine Hcl12$17,454
RexultiBrexpiprazole13$17,304
MounjaroTirzepatide15$14,627
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$12,816
LinzessLinaclotide15$10,512

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$224$89,75446 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta$593$81,645117 claims
Lilly USA, LLCTrulicity, Mounjaro$51$80,08866 claims
GSKTrelegy Ellipta$399$55,28650 claims
AbbVieCreon, Vraylar, Linzess$478$53,71547 claims
Boehringer IngelheimJardiance, Combivent Respimat$33$32,48452 claims
Otsuka America Pharmaceutical, Inc.Rexulti$352$17,30413 claims
BayerKerendia$229$7,99911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in Marion

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →